Literature DB >> 19748238

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.

Ryan C Anderson1, Christopher B Fox, Timothy S Dutill, Narek Shaverdian, Tara L Evers, Garrett R Poshusta, James Chesko, Rhea N Coler, Martin Friede, Steven G Reed, Thomas S Vedvick.   

Abstract

Immunostimulatory molecules such as monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist, can be formulated to enhance vaccine adjuvant effects and to promote a Th1-type immune response. This study compares the in vitro and in vivo potency of aqueous and emulsion formulations containing a synthetic MPL analogue. In addition, formulation structure and association of the synthetic TLR-4 agonist and antigen with the formulation are characterized using dynamic light scattering, zeta potential measurement, HPLC, and SDS-PAGE. The biological and biophysical effects of formulating the agonist with different oil and surfactant components from animal, plant, and synthetic sources are examined. These findings have important implications for the formulation of TLR4 agonists as well as the influence of formulation component substitution on adjuvant activity. The results indicate that (1) the agonist is associated with the oil droplets in emulsion formulations, (2) the emulsion formulations containing synthetic TLR4 agonist induce higher IgG2a/IgG1 antibody ratios than aqueous formulations or an emulsion formulation without the agonist, and (3) appropriate plant-derived components can be substituted for animal-derived components in oil-in-water emulsions without loss of biological activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748238     DOI: 10.1016/j.colsurfb.2009.08.022

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  44 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Angie Snell Bennett; Gaurav Manohar Rajani; Patrick McTamney; Krystal Nacel; Leigh Hostetler; Lily Cheng; Kuishu Ren; Terrence O'Day; Gregory A Prince; Michael P McCarthy
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Authors:  Pernille Nordly; Else Marie Agger; Peter Andersen; Hanne Mørck Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

4.  In vitro evaluation of TLR4 agonist activity: formulation effects.

Authors:  Ayesha Misquith; H W Millie Fung; Quinton M Dowling; Jeffrey A Guderian; Thomas S Vedvick; Christopher B Fox
Journal:  Colloids Surf B Biointerfaces       Date:  2013-09-19       Impact factor: 5.268

5.  Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

Authors:  Tina C Albershardt; Jardin Leleux; Andrea J Parsons; Jordan E Krull; Peter Berglund; Jan Ter Meulen
Journal:  NPJ Vaccines       Date:  2020-06-16       Impact factor: 7.344

6.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

7.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

8.  MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Authors:  Mark T Orr; Malcolm S Duthie; Hillarie Plessner Windish; Elyse A Lucas; Jeffrey A Guderian; Thomas E Hudson; Narek Shaverdian; Joanne O'Donnell; Anthony L Desbien; Steven G Reed; Rhea N Coler
Journal:  Eur J Immunol       Date:  2013-07-03       Impact factor: 5.532

9.  Adjuvant solution for pandemic influenza vaccine production.

Authors:  Christopher H Clegg; Richard Roque; Neal Van Hoeven; Lucy Perrone; Susan L Baldwin; Joseph A Rininger; Richard A Bowen; Steven G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

10.  Optimized subunit vaccine protects against experimental leishmaniasis.

Authors:  Sylvie Bertholet; Yasuyuki Goto; Lauren Carter; Ajay Bhatia; Randall F Howard; Darrick Carter; Rhea N Coler; Thomas S Vedvick; Steven G Reed
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.